Key result
Lipoprotein(a) lowering currently lacks randomized controlled trial evidence demonstrating clinical benefit, although elevated Lp(a) is an independent, causal risk factor for coronary heart disease.
Population
Patients with a family history of cardiovascular disease, those with several risk factors for CVD, and those…
Design
Review
Authors
Loading...
Lp(a) lowering should not guide therapy now; leaves open whether specific agents reduce events in RCTs.
While Lp(a) is an independent risk factor for coronary heart disease, specific Lp(a) lowering has not yet been proven to provide clinical benefit in randomized trials.
Koschinsky et al. (2014) conducted a review in Cardiovascular disease. Lipoprotein(a) lowering was evaluated. Lipoprotein(a) lowering currently lacks randomized controlled trial evidence demonstrating clinical benefit, although elevated Lp(a) is an independent, causal risk factor for coronary heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: